NASDAQ: SILO - Silo Pharma, Inc.

Rentabilität für sechs Monate: -50.49%
Sektor: Healthcare

Aktionsplan Silo Pharma, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.

Weitere Details
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Цена ао 1.94
Выручка 4.1E-5
EBITDA -0.000902
Число акций ао 0.00308 млрд
P/E 3.5
P/S 219.82
P/BV -389.57
EV/EBITDA -9.83
Сайт https://silopharma.com
Валюта usd
IPO date 2014-05-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Preisänderung pro Tag: -3.77% (1.06)
Preisänderung pro Woche: -3.77% (1.06)
Preisänderung pro Monat: -9.73% (1.13)
Preisänderung über 3 Monate: +5.92% (0.963)
Preisänderung über sechs Monate: -50.49% (2.06)
Preisänderung pro Jahr: -36.25% (1.6)
Preisänderung über 3 Jahre: +466.67% (0.18)
Preisänderung über 5 Jahre: +12 339.02% (0.0082)
Preisänderung seit Jahresbeginn: -35.85% (1.59)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 68.34 1
P/BV 0.7978 9
P/E 0 0
EV/EBITDA -0.364 0
Gesamt: 4.63

Effizienz

Name Bedeutung Grad
ROA, % -47.77 0
ROE, % -59.91 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 75.86 8
Rentabilität Ebitda, % 327.45 10
Rentabilität EPS, % -46.12 0
Gesamt: 7.6
Weitere Details

Institutionen Volumen Aktie, %
Financial Advocates Investment Management 62807 0.06
UBS Group AG 32843 0.03
Vanguard Group Inc 16334 0.02
Geode Capital Management, LLC 16179 0.02
TWO SIGMA SECURITIES, LLC 12788 0.01
State Street Corporation 12500 0.01
Tower Research Capital LLC (TRC) 7007 0.01
Westside Investment Management, Inc. 94 0
FWL INVESTMENT MANAGEMENT, LLC 80 0
Wells Fargo & Company 20 0

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
Avantis Emerging Markets Equity ETF 0.00003 11.542669584245 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.00246 15.961857379768 3.34087
Dimensional Emerging Markets Value ETF 0.00004 17.066115702479 4.19508
SPDR S&P Emerging Markets Small Cap ETF 0.01392 9.4592150479291 3.03583
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00179 12.462475271255 3.59676



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Eric Weisblum Chairman, President & CEO 569.01k 1970 (54 Jahr)
Mr. Daniel E. Ryweck Chief Financial Officer 62.69k 1965 (59 Jahre)
Dr. James S. Kuo M.B.A., M.D. Vice President of Research & Development N/A 1965 (59 Jahre)

Adresse: United States, Englewood Cliffs. NJ, 560 Sylvan Avenue - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://silopharma.com